I will lay odds that is what Gradalis are gambling on. If this plays the wrong way, and my instinct (sadly) is that it will, then BLT may have a problem with Gradalis being the first of several groups to flout BLT's patents where a degree of marginality is involved. One solution might be for BLT to seek a deal with a big pharma whereby big pharma fund legal costs in exchange for some of the action. Of course I hope I am wrong.
Does anyone have a good idea how strong BLT's case is from a legal standpoint?
Not investment advice.
BLT Price at posting:
45.0¢ Sentiment: None Disclosure: Held